ANNX
Annexon Inc.
Company Overview
| Mkt Cap | $336.25M | Price | $5.07 |
| Volume | 1.66M | Change | +3.47% |
| P/E Ratio | -2.4 | Open | $4.91 |
| Revenue | -- | Prev Close | $4.90 |
| Net Income | $-138.2M | 52W Range | $1.29 - $5.66 |
| Div Yield | N/A | Target | $14.00 |
| Overall | 61 | Value | 60 |
| Quality | 50 | Technical | 75 |
No chart data available
About Annexon Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Latest News
Annexon Biosciences (ANNX) Gets a Buy from Bank of America Securities
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANNX | $5.07 | +3.5% | 1.66M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |